Cargando…

Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders

Case series Patients: Female, 39-year-old • Female, 54-year-old • Female, 60-year-old Final Diagnosis: COVID-19 Symptoms: Fever Medication: — Clinical Procedure: — Specialty: Hematology • Nephrology • Rheumatology OBJECTIVE: Rare co-existance of disease or pathology BACKGROUND: Patients receiving im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araten, David J., Belmont, H. Michael, Schaefer-Cutillo, Julia, Iyengar, Arjun, Mattoo, Aprajita, Reddy, Ramachandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508305/ https://www.ncbi.nlm.nih.gov/pubmed/32917848 http://dx.doi.org/10.12659/AJCR.927418

Ejemplares similares

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
por: Amanam, Idoroenyi, et al.
Publicado: (2021)

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience
por: Amanam, Idoroenyi, et al.
Publicado: (2023)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

In vivo inhibition of the antibody response by a complement receptor- specific monoclonal antibody
Publicado: (1990)

Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies.
por: Price, M. R., et al.
Publicado: (1982)

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
por: Meyer, Saskia, et al.
Publicado: (2014)

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
por: Gulati, Sunita, et al.
Publicado: (2019)

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)

In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats
Publicado: (1994)

Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
por: Zelek, Wioleta M., et al.
Publicado: (2020)

Arthrogenicity of type II collagen monoclonal antibodies associated with complement activation and antigen affinity
por: Koobkokkruad, Thongchai, et al.
Publicado: (2011)

Monoclonal-antibodies: Severe course of COVID-19: 9 case reports
Publicado: (2021)

Bilateral Variation in the Origin and Course of the Vertebral Artery
por: Sikka, Aprajita, et al.
Publicado: (2012)

Activation of mouse peritoneal macrophages by monoclonal antibodies to Mac-1 (complement receptor type 3)
Publicado: (1987)

Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody
Publicado: (1983)

A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN
por: Hoekstra, Hedzer, et al.
Publicado: (2017)

Monoclonal antibodies effectively potentiate complement activation and phagocytosis of Staphylococcus epidermidis in neonatal human plasma
por: de Vor, Lisanne, et al.
Publicado: (2022)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
por: Arimura, Ken, et al.
Publicado: (2023)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

CONVERGENT VALIDITY OF QUALITY OF LIFE INTERVIEW (QOLI) IN AN INDIAN SETTING: PRELIMINARY FINDINGS
por: Lobana, Aprajita, et al.
Publicado: (2002)

PSYCHOMETRIC PROPERTIES OF QUALITY OF LIFE (QLS) SCALE : A BRIEF REPORT
por: Gupta, Nitin, et al.
Publicado: (2000)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Monoclonal antibody targeting complement C9 binding domain of Trichinella spiralis paramyosin impairs the viability of Trichinella infective larvae in the presence of complement
por: Hao, Yuwan, et al.
Publicado: (2014)

A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement
Publicado: (1995)

An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA
por: Thomas, K A, et al.
Publicado: (2015)

Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteins
por: Luo, Shen, et al.
Publicado: (2015)

Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species
por: Zelek, Wioleta M., et al.
Publicado: (2019)

Functional Analysis of a Novel Complement C5a Receptor 1-Blocking Monoclonal Antibody
por: Cyranka, Leon, et al.
Publicado: (2023)

Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis
por: Li, Lin-Lin, et al.
Publicado: (2019)

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022)

Emergency Department-based monoclonal antibody therapy for patients with mild to moderate COVID-19
por: Devlin, Amanda, et al.
Publicado: (2023)

Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
por: Makkouk, Amani, et al.
Publicado: (2015)

Evaluation of neonatal outcomes in COVID-19 positive mothers who received monoclonal antibodies
por: Chen, Katherine, et al.
Publicado: (2023)

Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.
por: Kosmas, C., et al.
Publicado: (1991)

CLINICAL COURSE OF ALCOHOL DEPENDENCE
por: Mattoo, S.K., et al.
Publicado: (1997)

Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H
por: Fülöp, Tamás, et al.
Publicado: (2018)

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies
por: Urban, Aleksandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nr4nrt1dhk2of7l3mqnfl18ho4